Incyte Corporation

This study tested a combination of two drugs, ipilimumab and epacadostat, in people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if adding epacadostat to standard treatment improved survival. However, the study was stopped early f…

This study tested whether adding the experimental drug parsaclisib to the standard drug ruxolitinib helps people with myelofibrosis whose spleen and symptoms haven't improved enough on ruxolitinib alone. The main goal was to see if the combination could shrink the spleen by at le…

This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…

This study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find safe doses and check for side effects, both when given alone and with other drugs. The trial was stopped early,…

This early-phase study tested a combination of two drugs (atezolizumab and epacadostat) in 29 adults with advanced lung or bladder cancer that had already been treated with chemotherapy. The goal was to check safety and find the right dose. The study was terminated early, so we h…

This early-phase study tested whether adding the drug itacitinib to standard anti-rejection medicines could help prevent graft-versus-host disease (GVHD) in people with blood cancers receiving a stem cell transplant. The study enrolled 84 participants and focused on safety and bl…

This study tested different drug combinations given before bladder removal surgery for people with muscle-invasive bladder cancer who could not take the standard chemotherapy drug cisplatin. The goal was to see how the drugs affected immune cells in the tumor. The study was stopp…

This early-stage study tested an experimental drug called INCB059872 in 25 people with Ewing sarcoma that had returned or stopped responding to standard treatments. The main goals were to check the drug's safety and see if it could shrink tumors. The study was ended early, so res…

This study tested a new drug called INCB000928 for people with anemia caused by myelodysplastic syndromes (MDS) or multiple myeloma. It was open to those who needed blood transfusions or had anemia symptoms. The study aimed to find a safe dose and check for side effects, but it w…

This study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in people with advanced solid tumors, including certain lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. The trial was terminated earl…

This study tested a drug called pemigatinib in 111 people with advanced solid tumors that have specific FGFR gene changes. The goal was to see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This early-stage study tested a new drug called INCB062079 in 25 people with advanced liver cancer or other solid tumors that had spread. The main goal was to check the drug's safety and find the best dose. The study was stopped early, so results are limited.

This study tested a drug called parsaclisib for people with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells, causing fatigue and low hemoglobin. The trial aimed to see if parsaclisib could raise hemoglobin levels and reduce fa…

This study tested a new experimental drug called INCA00186, alone or combined with other immunotherapies, in people with advanced solid tumors like head and neck or gastrointestinal cancers. The goal was to find a safe dose and see if it could shrink tumors. The study was termina…

This study tested a drug called ruxolitinib in 73 people with two types of blood cancer—polycythemia vera or essential thrombocythemia—that were not helped by standard treatment. The goal was to see if the drug could safely reduce high blood cell counts and symptoms like an enlar…

This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…

This study tested whether adding itacitinib to standard steroid treatment could help people with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 155 participants were enrolled. The trial was stopped early, so results …

This study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…

This early-phase study tested the drug itacitinib in 23 people who developed bronchiolitis obliterans syndrome (a type of lung scarring) after a double lung transplant. The goal was to see if it could safely improve lung function. The study was terminated early, so results are li…

This study tested whether adding an experimental drug (INCB001158) to a standard treatment (daratumumab) could help people with multiple myeloma that had returned or stopped responding to prior therapies. The trial enrolled 15 adults who had already tried at least 3 other treatme…

This study tested whether adding itacitinib to standard chemotherapy (docetaxel) could help people with advanced non-small cell lung cancer live longer. The trial was planned for two parts: first to find a safe dose, then to compare the combination against chemotherapy alone. How…

This study tested a drug called pemigatinib in people whose brain tumors (glioblastoma or other gliomas) had come back after prior treatment and had specific changes in FGFR1-3 genes. Participants took the drug daily for two weeks, then a week off, as long as they benefited. The …

This study aimed to see if adding itacitinib to standard steroids could safely treat acute graft-versus-host disease (aGVHD) in children after a stem cell transplant. Only 2 children were enrolled before the study was stopped early. The main goals were to check safety and how wel…

This study tested whether adding the drug parsaclisib to the standard treatment ruxolitinib could better shrink enlarged spleens and ease symptoms in people with myelofibrosis, a rare bone marrow cancer. The trial planned to enroll 252 adults with intermediate or high-risk diseas…

This study tested a new drug combination (pemigatinib plus pembrolizumab) versus pemigatinib alone or standard care for people with advanced bladder cancer that has a specific gene change (FGFR3) and cannot take the chemotherapy cisplatin. The goal was to see if the combination s…

This study tested a prescription cream called ruxolitinib on adults with mild-to-moderate eczema who had trouble sleeping because of their condition. The goal was to see if the cream could help them sleep longer and better. The study was stopped early, but it involved 47 particip…

This early-stage study aimed to check the safety and how the body handles a new drug called INCB000631 in 24 healthy adults aged 19 to 55. Participants would have taken multiple doses of the drug or a placebo. However, the study was terminated before completion, so no results are…